Search research articles
Contact Us
Filters
Showing results (441-450 of 627) with videos related to
Page
of 63
Sort By:
International Journal of Cardiology
|
November 18, 2008
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
Kenneth W Mahaffey, Simon T Tonev, Sarah A Spinler, et al.
The American Journal of Cardiology
|
August 18, 2014
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial)
Marco Valgimigli, Pierluigi Tricoci, Zhen Huang, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 18, 2026
Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW Trial
Katherine R Tuttle, Johannes F E Mann, Manuel M Mayrdorfer, et al.
Circulation
|
November 15, 2016
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease
W Schuyler Jones, Iris Baumgartner, William R Hiatt, et al.
Heart (British Cardiac Society)
|
March 12, 2008
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
R D Lopes, K S Pieper, J R Horton, et al.
Circulation
|
June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.
The American Journal of Cardiology
|
March 18, 2015
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
Jan H Cornel, Pierluigi Tricoci, Yuliya Lokhnygina, et al.
Heart (British Cardiac Society)
|
June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practice
Kyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
Journal of the American Heart Association
|
September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial
Anthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Richard E Pratley, Katherine R Tuttle, Peter Rossing, et al.
Page
of 63
Search research articles
Search
Showing results (441-450 of 627) with videos related to
Sort By:
Page
of 63
International Journal of Cardiology
|
November 18, 2008
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
Kenneth W Mahaffey, Simon T Tonev, Sarah A Spinler, et al.
The American Journal of Cardiology
|
August 18, 2014
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial)
Marco Valgimigli, Pierluigi Tricoci, Zhen Huang, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 18, 2026
Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW Trial
Katherine R Tuttle, Johannes F E Mann, Manuel M Mayrdorfer, et al.
Circulation
|
November 15, 2016
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease
W Schuyler Jones, Iris Baumgartner, William R Hiatt, et al.
Heart (British Cardiac Society)
|
March 12, 2008
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
R D Lopes, K S Pieper, J R Horton, et al.
Circulation
|
June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.
The American Journal of Cardiology
|
March 18, 2015
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
Jan H Cornel, Pierluigi Tricoci, Yuliya Lokhnygina, et al.
Heart (British Cardiac Society)
|
June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practice
Kyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
Journal of the American Heart Association
|
September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial
Anthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Richard E Pratley, Katherine R Tuttle, Peter Rossing, et al.
Page
of 63